anti-MIF siRNA nanoparticles

Anti-MIF siRNA nanoparticles are a preclinical non-viral gene therapy system developed at Case Western Reserve University for the treatment of breast cancer and other solid tumors. The system utilizes a biodegradable 10 kDa β-glucan (BG34-10) backbone modified with protonable imidazole at the reducing end (designated as BG34-10-Re-I) to encapsulate small interfering RNA (siRNA) targeting macrophage migration inhibitory factor (MIF). The glucan shell facilitates active uptake by macrophages and tumor cells, while the imidazole provides buffering capacity to induce endosomal escape. Once in the cytosol, the slow degradation of the glucan shell allows for the sustained release of siRNA, leading to a prolonged reduction of MIF expression. In preclinical models of mammary tumors, intratumoral or systemic administration of these nanoparticles significantly reduces primary tumor growth, decreases metastasis, and alleviates tumor-induced immunosuppression by reducing circulating myeloid-derived suppressor cells (MDSCs).

Other names

BG34-10-Re-I/siRNA nanoparticlesglucan-based anti-MIF siRNA nanoparticlesglucan-based siRNA nanoparticles